Delving into the Latest Updates on Intravitreal ranibizumab(Sultan Qaboos University Hospital) with Synapse

Overview

Basic Info

Drug Type

Fab fragment, Biosimilar

Synonyms

Intravitreal ranibizumab(Sultan Qaboos University Hospital), Ranibizumab biosimilar (Sultan Qaboos University Hospital), 雷珠单抗生物类似药 (Sultan Qaboos University Hospital)

Target

VEGF-A

Mechanism

VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)

Therapeutic Areas

Congenital DisordersEye Diseases

Active Indication

Retinal Dysplasia

Inactive Indication

Biallelic RPE65 mutation associated retinal dystrophy

Originator Organization

Sultan Qaboos University Hospital

Active Organization

Sultan Qaboos University Hospital

Inactive Organization

University of Sultan Qaboos

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 103170L

The sequence is quoted from: *****

Sequence Code 143622H

The sequence is quoted from: *****

To evaluate the efficacy and safety of intravitreal ranibizumab (IVR) injection in the treatment of non-leaking macular cysts in patients with retinal dystrophy.
Material and Methods:
Design - Prospective, nonrandomized, nonblinded, clinical trial. Participants - Patients >18 years diagnosed with retinal dystrophies and non-leaking macular cysts between Jan 2015 and July 2018 in 1 center.
Methods - Phase 1: Patients with best corrected visual acuity (BCVA) < 0.5 will receive carbonic anhydrase inhibitors (CAI) [oral acetazolamide 500mg/day or topical brinzolamide twice daily] and followed up for three months. Phase 2: Patients who do not show an adequate response with CAI will receive three 0.5mg IVR injection at monthly intervals.
Outcome - 1) Significant reduction (> 10%) of the central macular thickness (CMT), 2) Improvement (> 1 line) in BCVA 3) Presence of any complication.

Start Date24 Jul 2015

Sponsor / Collaborator

University of Sultan Qaboos

NCT02933905

/ CompletedNot ApplicableIIT

Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection

Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors

Start Date01 Jan 2014

Sponsor / Collaborator-

100 Clinical Results associated with Intravitreal ranibizumab(Sultan Qaboos University Hospital)

Login to view more data

100 Translational Medicine associated with Intravitreal ranibizumab(Sultan Qaboos University Hospital)

Login to view more data

100 Patents (Medical) associated with Intravitreal ranibizumab(Sultan Qaboos University Hospital)

Login to view more data

493

Literatures (Medical) associated with Intravitreal ranibizumab(Sultan Qaboos University Hospital)

18 Nov 2024·International Journal of Ophthalmology

Short-term fluctuation of intraocular pressure and influencing factors following intravitreal injection in patients with retinal vascular diseases

Article

Author: Miao, Jing-Peng ; Zeng, Yi-Yun ; Gu, Xin-Ming ; Gu, Xin-Ming ; Zhang, Xin-Yuan ; Zhang, Xin-Yuan

AIM: To investigate the patterns of short-term intraocular pressure (IOP) fluctuations and identify the contributing factors following intravitreal injection in patients with retinal vascular diseases. METHODS: Totally 81 patients were enrolled in this case control study. Eyes were categorized into 7 groups, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), idiopathic choroidal neovascularization (CNV), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), macular edema secondary to branch (BVOME) and central (CVOME) retinal vein occlusion. IOP was measured in all patients using rebound tonometer at 7 preset time points perioperatively. Additionally, based on the administered medication, the eyes were classified into three treatment groups, including dexamethasone intravitreal implant (IVO), intravitreal conbercept (IVC), and intravitreal ranibizumab (IVR). To compare IOP values at various time points across groups, we employed one-way ANOVA, independent sample t-test or χ2 test and multivariate logistic regression analysis. RESULTS: Peak IOP values across all groups were observed at 40s, and 5min after intravitreal injection. Statistical differences in IOP were detected at the 5min among the 7 indication groups (F=2.50, P=0.029). When examing the impact of medications, the IVO group exhibited lower average IOP values at both 40s and 5min compared to the IVC and IVR groups (P<0.001; P=0.007). The IOP values at 40s and 5min were significantly higher in BVOME and CVOME group compared to non-retinal vein occlusion-secondary macular edema (RVOME) group (P<0.001). Multivariate logistic regression analysis further confirmed that IOP measurement at 40s was significantly higher in CVOME group than in non-RVOME group (OR=1.64, 95%CI: 1.09-2.47; P=0.018). CONCLUSION: Needle size plays a crucial role in the transient changes of IOP following intravitreal injection. Before administering intravitreal injection to patients with central retinal vein occlusion, it is essential to exclude any underlysing causes of increased IOP.

02 Jul 2024·Cureus

Comparison of Intravitreal Ranibizumab and Laser Photocoagulation in the Treatment of Type I Retinopathy of Prematurity in Malaysia: A One-Year Follow-Up Study

Article

Author: Rahmat, Jamalia ; Syahmi, Md Razali ; Wardati H, Jami ; Hamzah, Norhafizah ; Khadijah, Mustafa ; Nurul-Farhana, Mustafa ; Lai, Yoon Kit Ivan ; Shatriah, Ismail ; Chew, Fiona Lee Min ; Karimmah, Wahit

PURPOSEThis study aimed to evaluate the treatment efficacy, anatomical outcomes, and refractive outcomes of laser photocoagulation (LPC) and intravitreal ranibizumab (IVR) in the treatment of type I retinopathy of prematurity (ROP) at one-year follow-up.METHODSThis is a retrospective study on the treatment of type I ROP and aggressive ROP (A-ROP) using LPC or IVR in three Malaysian hospitals providing pediatric ophthalmology services from January 2019 to December 2021. Information on gestational age, birth weight, ROP zone and stage, and underlying comorbidities was collected. Parameters for evaluating treatment efficacy include the time taken to achieve complete regression, the regression rate, and the reactivation rate. The anatomical and refractive outcomes were evaluated at one year of adjusted age.RESULTSThis study included 92 eyes from 46 infants. Of these, 42 eyes received LPC as the initial treatment, while 50 eyes underwent IVR. A higher percentage of infants with cardiovascular disease were treated with IVR (66.7%) compared to LPC (40%) (p<0.05). However, there were no significant differences in gestational age, birth weight, respiratory distress syndrome, sepsis, or intraventricular hemorrhage between the two treatment groups (p>0.05). Infants treated with LPC had a higher regression rate than those treated with IVR, but they were also significantly more myopic and had worse best-corrected visual acuity (BCVA). Conversely, infants treated with IVR experienced a significantly higher reactivation rate compared to those treated with LPC. Logistic regression analysis showed no significant associations between gestational age, birth weight, plus disease, zone 1 ROP, and the choice of initial treatment with the reactivation of ROP.CONCLUSIONSBoth LPC and IVR effectively treat type I ROP in infants, with IVR yielding superior anatomical and refractive outcomes and LPC offering a lower reactivation rate. Understanding individual patient characteristics is crucial for treatment selection.

18 Apr 2024·International Journal of Ophthalmology

Effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized versus non-vitrectomized eyes: a Meta-analysis

Article

Author: Wang, Yi-Heng ; Xu, Qian ; Luan, Jie

AIM: To evaluate the effectiveness and safety of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) in vitrectomized versus non-vitrectomized eyes. METHODS: The PubMed, EMBASE, Web of Science, Cochrane, EBSCO were comprehensively searched for studies comparing vitrectomized and non-vitrectomized eyes with DME. Clinical outcomes of best-corrected visual acuity (BCVA), central macular thickness (CMT), the mean number of intravitreal injection and adverse events were extracted and analyzed. RESULTS: Six studies involving 641 eyes were included. Final visual gain significantly improved and CMT significantly reduced in vitrectomized eyes at 6mo and 12mo visits (P<0.05). Although the mean reduction in CMT among non-vitrectomized eyes was significantly greater than in vitrectomized eyes at the 6mo [mean difference (MD)=53.57, 95% confidence interval (CI): 28.03 to 78.72, P<0.0001] and 12mo (MD=49.65, 95%CI: 19.58 to 79.72, P=0.01), no significant difference was detected in improvement in BCVA at either 6mo (MD=0.05, 95%CI: -0.02 to 0.13, P=0.14) or 12mo (MD=0.03, 95%CI: -0.04 to 0.09, P=0.43). Injection number of ranibizumab in non-vitrectomized eyes was significantly less than that in vitrectomized eyes during 6-month period (MD=0.60, 95%CI: 0.16 to 1.04, P=0.008), while there was no statistically significant difference between the two groups during 12mo of follow-up. CONCLUSION: Evidence from current study suggests that IVR was useful for both vitrectomized group and non-vitrectomized group with DME. Although less reduction in macular thickness is found in vitrectomized group, visual improvement between two groups is similar.

100 Deals associated with Intravitreal ranibizumab(Sultan Qaboos University Hospital)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S01LA04	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Biallelic RPE65 mutation associated retinal dystrophy	Phase 2	-	University of Sultan Qaboos	24 Jul 2015
Retinal Dysplasia	Phase 2	-	Sultan Qaboos University Hospital	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2024	Not Applicable	Retinopathy of Prematurity	131	Intravitreal injection of Ranibizumab 0.25 mg/0.025 ml	gugosqrbit(nibrwowldj) = exirvecjit zytfgkujcd (eetaekmvjs, 1.37) View more	Positive	19 Sep 2024
ARVO2023	Not Applicable	Retinopathy of Prematurity First line	44	Intravitreal ranibizumab 0.2 mg	zhocpiqlsy(gaeilrbwlq) = fanljpslkj oqlxfjlcry (vjkvpxkewm ) View more	-	01 Jun 2023
APAO2023	Not Applicable	Myopic choroidal neovascularization	14	Intravitreal Ranibizumab Injection	(nayqrjxqdx) = trdlwpkciw amzpjvvuvl (upnmnjsouz ) View more	Positive	23 Feb 2023
EURETINA2022	Not Applicable	Diabetic macular oedema \| Wet age-related macular degeneration	-	Intravitreal Ranibizumab Biosimilar	(phsrrttmkw) = czgzqtlfyh btoylrrdvv (vjomjhwxvc ) View more	Positive	01 Sep 2022
EURETINA2022	Not Applicable	Wet age-related macular degeneration	-	Intravitreal ranibizumab (0.5 mg)	sotamlhxov(kaukgyogad) = decrease of PWV after the first (by 0.34 m/s) and the second injection (by 0.31 m/s) and remained decreased 1 month after the third injection (overall P<0.05) rblmkcfakj (dedtcxrtff ) View more	-	01 Sep 2022
				Placebo
APAO2021	Not Applicable	Retinal Vein Occlusion	81	Intravitreal Ranibizumab Monthly	(nzlpdutpre) = lcvmbdkvbn uswagzytmy (tpnmdsdvxp, 193.18)	Positive	05 Sep 2021
				Intravitreal Ranibizumab PRN	(nzlpdutpre) = ndrirsstjl uswagzytmy (tpnmdsdvxp, 108.92)
APAO2021	Not Applicable	Choroidal Neovascularization	-	Intravitreal Ranibizumab Monthly Protocol	kcjjkjhjzu(kiidwyiqya) = mgmjqjjwfv cxwcuqfozb (ikaosxjpvn ) View more	-	05 Sep 2021
				Intravitreal Ranibizumab PRN Protocol	kcjjkjhjzu(kiidwyiqya) = qgjgoynwdj cxwcuqfozb (ikaosxjpvn ) View more
APAO2021	Not Applicable	Diabetic Retinopathy	-	Monthly Intravitreal Ranibizumab	oypwqtcxqc(sfzghebccn) = lsezvbkjni luoyznscxk (kzzqglszmd, 73.25)	-	05 Sep 2021
				Pro Re Nata (PRN) Intravitreal Ranibizumab	oypwqtcxqc(sfzghebccn) = bxkozwuiue luoyznscxk (kzzqglszmd, 63.05)
EURETINA2021	Not Applicable	Retinal vein occlusion-related macular edema	-	Intravitreal injection of Ranibizumab	(bfggctiaav) = grwwegnjca wpufmemfqo (zdouomrchs ) View more	-	01 Sep 2021
ARVO2018	Phase 2	Macular Edema	40	Intravitreal Ranibizumab Monthly	(wofmpnqyeq) = oxkukmvrxk hpcuzxvgeq (zxptmhyukz )	-	01 Jul 2018
				Intravitreal Ranibizumab Monthly with targeted PRP	(wofmpnqyeq) = dyncsuvvxg hpcuzxvgeq (zxptmhyukz )